Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Short Interest Update

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 43,518 shares, a decrease of 59.8% from the June 15th total of 108,354 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 20,766 shares, the days-to-cover ratio is presently 2.1 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ZYBT. Jane Street Group LLC acquired a new stake in Zhengye Biotechnology during the second quarter worth approximately $1,158,000. WINTON GROUP Ltd grew its position in shares of Zhengye Biotechnology by 193.8% in the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock valued at $73,000 after purchasing an additional 41,750 shares during the last quarter. Invesco Ltd. acquired a new position in shares of Zhengye Biotechnology in the second quarter valued at approximately $220,000. Geode Capital Management LLC bought a new position in shares of Zhengye Biotechnology during the second quarter worth approximately $174,000. Finally, XTX Topco Ltd increased its stake in shares of Zhengye Biotechnology by 71.4% during the fourth quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after purchasing an additional 24,697 shares during the period.

Zhengye Biotechnology Trading Up 2.6%

Shares of Zhengye Biotechnology stock opened at $0.80 on Monday. The company has a quick ratio of 0.82, a current ratio of 1.14 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $0.83 and a two-hundred day simple moving average of $0.93. Zhengye Biotechnology has a 1 year low of $0.62 and a 1 year high of $13.08.

Zhengye Biotechnology (NASDAQ:ZYBT) last released its quarterly earnings data on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The business had revenue of $3.97 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.